Cytek Biosciences Acquires Flow Cytometry Business from DiaSorin

Facebook X LinkedIn Email
Cytek Biosciences has signed an agreement with DiaSorin subsidiary Luminex to acquire substantially all of its assets related to the Flow Cytometry and Imaging (FCI) business unit. The acquisition will expand Cytek’s global footprint and add two product lines, the Amnis and Guava series of flow cytometers, to its existing portfolio, Cytek said.

Financial details of the transaction were not disclosed.

The sale is expected to close within 30 days, subject to customary closing conditions. The companies dated the announcement of the transaction Feb. 13.

The FCI business unit, acquired by Luminex in October 2018 for $75 million from MilliporeSigma, is based on both conventional flow cytometry and image-based flow cytometry instrumentation. The unit includes dedicated commercial, operations, R&D, and supporting personnel, as well as an existing installed base of more than 7000 instruments. 

In November 2021, Cytek acquired the cell analysis business of Tonbo Biosciences, which included a portfolio of life science research reagents related to flow cytometry as well as other methods. The addition came less than a year after Cytek closed its $120 million series D funding round.

Published: February 2023
flow cytometry
Flow cytometry is a powerful technique used in biology and medicine for the quantitative analysis of the physical and chemical characteristics of cells and particles suspended in a fluid. The method allows for the rapid measurement of multiple parameters simultaneously on a cell-by-cell basis. It is widely used in various fields, including immunology, microbiology, hematology, and cancer research. Here are the key components and features of flow cytometry: Sample preparation: Cells or...
Businessacquisitionsmergers & acquisitionsflow cytometryBiophotonicsImagingcell analysisphenotypingAmericasEuropeCytek BiosciencesDiaSorinLuminexIndustry NewsBioScan

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.